The Ridgewood Blog Brings a Free Market Laissez-faire Point of View to Local, New Jersey State and National Issues.
the staff of the Ridgewood blog
West Orange NJ, RWJBarnabas Health is proud to have been a participant in one of the Gilead trials to assess antiviral Remdesivir as a treatment for patients with severe COVID-19. Gilead recently announced promising top line results that show similar efficacy with 5- and 10- day dosing durations of the drug.
the staff of the Ridgewood blog
Ridgewood NJ, A promising drug called remdesivir may shorten hospital stays for patients with COVID-19 and perhaps speed their recoveries while diminishing the odds of death, according to Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, who on Wednesday described federal next steps based on the new, positive study.
the staff of the Ridgewood blog
FOSTER CITY Calif, Gilead Sciences, Inc. (Nasdaq: GILD) today announced the initiation of two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19 (novel coronavirus). These randomized, open-label, multicenter studies will enroll approximately 1,000 patients at medical centers primarily across Asian countries, as well as other countries globally with high numbers of diagnosed cases, beginning in March. The studies will assess two dosing durations of remdesivir, administered intravenously. The initiation of these studies follows the U.S. Food and Drug Administration’s (FDA) rapid review and acceptance of Gilead’s investigational new drug (IND) filing for remdesivir for the treatment of COVID-19.
